ChiCTR2500105671 版本V1.1 版本创建时间2025/12/01 15:56:20 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500105671 

最近更新日期:

Date of Last Refreshed on:

2025-07-09 08:15:27 

注册时间:

Date of Registration:

2025-07-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

间歇性外斜视患者眼位控制影响因素及潜在神经机制的研究

Public title:

Research on the Influencing Factors and Potential Neural Mechanisms of Eye Position Control in Patients with Intermittent Exotropia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

关于间歇性外斜视眼位控制的研究

Scientific title:

Research on the Control of Eye Position in Intermittent Exotropia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

潘鑫源 

研究负责人:

杨智宽 

Applicant:

Xinyuan Pan 

Study leader:

Zhikuan Yang 

申请注册联系人电话:

Applicant telephone:

+86 180 0963 1364

研究负责人电话:

Study leader's
telephone:

+86 133 8007 1988

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

516032162@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yangzhikuan@aierchina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市天心区芙蓉南路188号

研究负责人通讯地址:

湖南省长沙市天心区芙蓉南路188号

Applicant address:

No. 188, Furong South Road, Tianxin District, Changsha, Hunan

Study leader's address:

No. 188, Furong South Road, Tianxin District, Changsha, Hunan

申请注册联系人邮政编码:

Applicant postcode:

410015

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长沙爱尔眼科医院

Applicant's institution:

Changsha Aier Eye Hospital

研究负责人所在单位:

长沙爱尔眼科医院

Affiliation of the Leader:

Changsha Aier Eye Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

长爱伦审字(2024) KYPJ039号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

爱尔眼科医院集团股份有限公司长沙爱尔眼科医院伦理委员会

Name of the ethic committee:

Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-03 00:00:00

伦理委员会联系人:

方静

Contact Name of the ethic committee:

Jing Fang

伦理委员会联系地址:

湖南省长沙市天心区芙蓉南路188号

Contact Address of the ethic committee:

No. 188, Furong South Road, Tianxin District, Changsha, Hunan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8522 3462

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长沙爱尔眼科医院

Primary sponsor:

Changsha Aier Eye Hospital

研究实施负责(组长)单位地址:

湖南省长沙市天心区芙蓉南路188号

Primary sponsor's address:

No. 188, Furong South Road, Tianxin District, Changsha, Hunan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙爱尔眼科医院

具体地址:

湖南省长沙市天心区芙蓉南路188号

Institution
hospital:

Changsha Aier Eye Hospital

Address:

No. 188, Furong South Road, Tianxin District, Changsha, Hunan

经费或物资来源:

自筹

Source(s) of funding:

Self-finance

研究疾病:

间歇性外斜视  

Target disease:

Intermittent Exotropia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1、探索诱发IXT患者眼位偏斜的关键视觉因素并量化关键视觉因素诱发IXT患者眼位偏斜的动态过程。 2、基于视觉通路加工特点进一步探究IXT发病的神经机制。  

Objectives of Study:

1. Exploring the key visual factors that trigger eye deviation in patients with IXT and Quantifying the dynamic process by which key visual factors induce eye deviation in patients with IXT 2. Based on the processing characteristics of the visual pathway, further explore the neural mechanism underlying the onset of IXT.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄8-40岁,单眼最佳矫正视力≤0.00 logMAR; (2)除屈光不正外无其他眼病及全身疾病,无眼部手术史、外伤史; (3)发生外斜的斜视角度≥10棱镜度; (4)NCS/MOCS评分≤3,视远、视近均可控制正位; (5)愿意并能够配合佩戴眼动仪1个小时以上,等效球径度在+4.00D-6.00D之间(使用眼动仪内置镜片)或在佩戴隐形眼镜进行屈光矫正。

Inclusion criteria

(1) Age 8-40 years, with best-corrected visual acuity <=0.00 logMAR in either eye; (2) No ocular or systemic diseases other than refractive error, and no history of ocular surgery or trauma; (3) Manifest exodeviation >=10 prism diopters; (4) NCS or MOCS score <=3 with orthophoria control at both distance and near; (5) Willingness and ability to cooperate with eye tracker wear for >1 hour, with spherical equivalent between +4.00D to +6.00D (using built-in corrective lenses) or with refractive correction via contact lenses.

排除标准:

(1)等效球径度超过+4.00D~-6.00D且不愿佩戴隐形眼镜进行检查者; (2)拒绝签署书面知情同意或无法坚持配合完成全部检查过程者;

Exclusion criteria:

(1) Subjects with spherical equivalent outside the -6.00D to +4.00D range who decline refractive correction via contact lenses; (2) Subjects refusing to sign written informed consent or unable to maintain cooperation throughout the entire examination protocol.

研究实施时间:

Study execute time:

From 2025-07-14 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-14 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

80

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙爱尔眼科医院 

单位级别:

三级 

Institution
hospital:

Changsha Aier Eye Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

水平方向双眼聚散角(θ)

指标类型:

主要指标

Outcome:

Horizontal Binocular Vergence Angle (θ)

Type:

Primary indicator

测量时间点:

测量方法:

可穿戴式眼动仪

Measure time point of outcome:

Measure method:

The wearwable eye tracker

指标中文名:

眼间抑制度

指标类型:

主要指标

Outcome:

The degree of biocular inhibition

Type:

Primary indicator

测量时间点:

测量方法:

双眼方向整合任务

Measure time point of outcome:

Measure method:

The binocular orientation combination task

指标中文名:

眼位控制力评分(NCS/MCOS)

指标类型:

主要指标

Outcome:

Eye position control score(NCS/MCOS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

三棱镜交替遮盖试验(6m及33cm)

指标类型:

主要指标

Outcome:

Prism and Alternate Cover Test(6m and 33cm)

Type:

Primary indicator

测量时间点:

测量方法:

三棱镜

Measure time point of outcome:

Measure method:

Prism

指标中文名:

不同遮盖条件下眼动仪所的记录双眼运动轨迹

指标类型:

主要指标

Outcome:

The recorded binocular movement trajectories of the eye tracker under different occlusion conditions.

Type:

Primary indicator

测量时间点:

测量方法:

可穿戴式眼动仪

Measure time point of outcome:

Measure method:

The wearwable eye tracker

指标中文名:

worth四点灯检查

指标类型:

次要指标

Outcome:

Worth 4-Dot test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

立体视检查(远、近)

指标类型:

次要指标

Outcome:

Stereopsis (far and near)

Type:

Secondary indicator

测量时间点:

测量方法:

随机点立体图

Measure time point of outcome:

Measure method:

Random dot stereogram

指标中文名:

同视机检查

指标类型:

次要指标

Outcome:

Synoptophore

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:病例记录表和电子采集 数据管理:病例记录表和电子管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: Case record form and electronic collection Data management: Case record form and electronic management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-07-09 08:15:22